The risk of transfusion transmitted infections (TTI, including HIV, HBV and HCV) has decreased significantly in recent years in developed countries. Unfortunately, many developing countries still have TTI risk levels that are significantly higher than developed countries.
Dr. Shan has focused her work on developing collaborative research programs with international blood centers with the purpose of identifying ways to improve international blood safety.
- Shan H, Zhang P. “Viral Attack On Blood Collection: The Experience From Beijing During The SARS Epidemic.” Transfusion. 2004; 44:467-469.
- Mattis L, Shan H, Powell E, Shirey S, Oliva-Hemker M. “Life threatening ceftriaxone-induced hemolytic anemia in a child with Crohn's disease.” Clinical Pediatrics. 2004; 43:175-178.
- Shan H, Piwowar-Manning E, Thompson RE, Brooks Jackson J. “HIV-1 plasma RNA level and CD4 cell count in a large urban HIV-1-infected patient population from 1997 to 2000.” Int J STD AIDS. 2003 Nov;14(11):740-4.
- Shan H, Wang J-X, Ren F-R, Zhang Y-Z, Zhao H-Y, Gao G-J, Ji Y, Ness PM. “Blood Banking in China.” The Lancet. 2002. 360(9347):1770-1775.
The Shan lab has carried out donor follow-up case controlled studies in blood centers in Beijing and Urumqi, China to identify risk factors associated with donor HIV and HCV infections. The reported common risk factors among donors in the United States include a history of injection drug abuse (IDU) and a history of blood transfusion before 1990. The lab’s preliminary findings from Chinese blood centers revealed the history of whole blood or plasma donation prior to 1995 as a leading risk factor for both HIV and HCV infections.
The current donor deferral criteria used at Chinese blood centers does not defer donors with donation history prior to 1995. Based on their findings, the lab is proposing changes to the existing donor deferral criteria to more effectively prevent high-risk donors from entering the donor pool.
The lab is also conducting a multi-blood center study using the nucleic acid based donor test (NAT) to evaluate the prevalence, incidence, and the residual risk level of HIV and HCV in China. They have recently completed a knowledge, attitude and practice (KAP) survey in Urumqi, China to gain better understanding of potential donors in order to develop more effective donor recruitment methods. In addition, they are currently conducting a study in Beijing searching for inexpensive HCV confirmatory methods (instead of the RIBA test, as used in developed countries) that can be used in resource-poor countries.